Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer.

Cancer Commun (Lond) · 2023 · PMC10397558 · PMID 37278484

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

tended towards significanceP = 0.066so close (0.05 < p ≤ 0.1)

HR+/HER2‐) tended towards significance by univariate interaction analysis ( P = 0.066), with a stronger benefit of pembrolizumab addition in TN tumors (Figure 1B ).

also in 32 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.